P2.01-04 An Update on the CONCORDE study: A Phase Ib Platform Study of Novel Agents in Combination With Conventional Radiotherapy in NSCLCA. Horne, A. Greystoke, M. Hatton et al.|Journal of Thoracic Oncology|2023Cited by 2
MA09.03 Plasma Proteomics-based Models for Predicting Immunotherapy- and Chemotherapy-Related Toxicity in NSCLC PatientsJarushka Naidoo, Yehonatan Elon, David R. Gandara et al.|Journal of Thoracic Oncology|2024Cited by 0
P3.13C.02 A Plasma Proteomics-Based Model for Clinical Benefit Prediction in Small Cell Lung Cancer Patients Receiving ImmunotherapyDavid R. Gandara, M.A. Schneider, David P. Carbone et al.|Journal of Thoracic Oncology|2024Cited by 0